{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T15:17:45Z","timestamp":1772551065577,"version":"3.50.1"},"reference-count":85,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Behavioural Brain Research"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1016\/j.bbr.2011.06.011","type":"journal-article","created":{"date-parts":[[2011,6,26]],"date-time":"2011-06-26T06:58:00Z","timestamp":1309071480000},"page":"336-343","source":"Crossref","is-referenced-by-count":91,"title":["Antidepressant-like effect of pioglitazone in the forced swimming test in mice: The role of PPAR-gamma receptor and nitric oxide pathway"],"prefix":"10.1016","volume":"224","author":[{"given":"Mohammad Salehi","family":"Sadaghiani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehrak","family":"Javadi-Paydar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Hadi","family":"Gharedaghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yashar Yousefzadeh","family":"Fard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad Reza","family":"Dehpour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbr.2011.06.011_bib0005","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0006-3223(02)01423-3","article-title":"Depression as a risk factor for non-suicide mortality in the elderly","volume":"52","author":"Schulz","year":"2002","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.bbr.2011.06.011_bib0010","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1146\/annurev.clinpsy.3.022806.091444","article-title":"Prevalence, comorbidity, and service utilization for mood disorders in the United States at the beginning of the twenty-first century","volume":"3","author":"Kessler","year":"2007","journal-title":"Annu Rev Clin Psychol"},{"key":"10.1016\/j.bbr.2011.06.011_bib0015","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/nrn1846","article-title":"New approaches to antidepressant drug discovery: beyond monoamines","volume":"7","author":"Berton","year":"2006","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.bbr.2011.06.011_bib0020","doi-asserted-by":"crossref","first-page":"415","DOI":"10.7326\/0003-4819-143-6-200509200-00006","article-title":"Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder","volume":"143","author":"Hansen","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bbr.2011.06.011_bib0025","doi-asserted-by":"crossref","first-page":"734","DOI":"10.7326\/0003-4819-149-10-200811180-00008","article-title":"Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians","volume":"149","author":"Gartlehner","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bbr.2011.06.011_bib0030","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1055\/s-2007-979217","article-title":"The importance of new antidepressants in the treatment of anxiety\/depressive disorders","volume":"32","author":"Boerner","year":"1999","journal-title":"Pharmacopsychiatry"},{"issue":"Suppl.","key":"10.1016\/j.bbr.2011.06.011_bib0035","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1038\/nn943","article-title":"Treatment of mood disorders","volume":"5","author":"Nemeroff","year":"2002","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.bbr.2011.06.011_bib0040","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.genhosppsych.2009.07.009","article-title":"The impact of diabetes on depression treatment outcomes","volume":"32","author":"Bryan","year":"2010","journal-title":"Gen Hosp Psychiatry"},{"key":"10.1016\/j.bbr.2011.06.011_bib0045","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/toxsci\/kfp126","article-title":"Diabetes impairs hippocampal function via advanced glycation end product mediated new neuron generation in animals with diabetes-related depression","volume":"111","author":"Wang","year":"2009","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.bbr.2011.06.011_bib0050","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s00125-007-0873-z","article-title":"Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. Update regarding the thiazolidinediones","volume":"51","author":"Nathan","year":"2008","journal-title":"Diabetologia"},{"key":"10.1016\/j.bbr.2011.06.011_bib0055","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1161\/CIRCULATIONAHA.107.704080","article-title":"New drugs for the treatment of diabetes mellitus: part I: Thiazolidinediones and their evolving cardiovascular implications","volume":"117","author":"McGuire","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.bbr.2011.06.011_bib0060","first-page":"263","article-title":"Effects of pioglitazone on glucose and lipid metabolism in Wistar fatty rats","volume":"40","author":"Sugiyama","year":"1990","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.bbr.2011.06.011_bib0065","doi-asserted-by":"crossref","unstructured":"Ramanan S, Zhao W, Riddle DR, Robbins ME. Role of PPARs in radiation-induced brain injury. PPAR Res. 2010:234975.","DOI":"10.1155\/2010\/234975"},{"key":"10.1016\/j.bbr.2011.06.011_bib0070","doi-asserted-by":"crossref","first-page":"403896","DOI":"10.1155\/2008\/403896","article-title":"PPARs in Alzheimer's disease","volume":"2008","author":"Kummer","year":"2008","journal-title":"PPAR Res"},{"key":"10.1016\/j.bbr.2011.06.011_bib0075","doi-asserted-by":"crossref","first-page":"517162","DOI":"10.1155\/2008\/517162","article-title":"Potential therapeutic targets for PPARgamma after spinal cord injury","volume":"2008","author":"McTigue","year":"2008","journal-title":"PPAR Res"},{"key":"10.1016\/j.bbr.2011.06.011_bib0080","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/ncpneuro0586","article-title":"Drug insight: effects mediated by peroxisome proliferator-activated receptor-gamma in CNS disorders","volume":"3","author":"Heneka","year":"2007","journal-title":"Nat Clin Pract Neurol"},{"key":"10.1016\/j.bbr.2011.06.011_bib0085","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.neuropharm.2009.10.008","article-title":"Activation of peroxisome proliferator-activated receptor gamma in brain inhibits inflammatory pain, dorsal horn expression of Fos, and local edema","volume":"58","author":"Morgenweck","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bbr.2011.06.011_bib0090","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1176\/appi.ajp.2008.08081195","article-title":"Antidepressant response associated with pioglitazone: support for an overlapping pathophysiology between major depression and metabolic syndrome","volume":"166","author":"Kemp","year":"2009","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.bbr.2011.06.011_bib0095","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.pnpbp.2008.05.020","article-title":"Antidepressant-like effect of the novel thiadiazolidinone NP031115 in mice","volume":"32","author":"Rosa","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.bbr.2011.06.011_bib0100","unstructured":"Antidepressant-like effects of rosiglitazone, a PPARgamma agonist, in the rat forced swim and mouse tail suspension tests. Behav Pharmacol 2009."},{"key":"10.1016\/j.bbr.2011.06.011_bib0105","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.arcmed.2009.05.005","article-title":"Pro12Ala polymorphism in PPARgamma2 associated with depression in Chinese nonagenarians\/centenarians","volume":"40","author":"Ji-Rong","year":"2009","journal-title":"Arch Med Res"},{"key":"10.1016\/j.bbr.2011.06.011_bib0110","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.neuroscience.2003.08.064","article-title":"Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS","volume":"123","author":"Moreno","year":"2004","journal-title":"Neuroscience"},{"key":"10.1016\/j.bbr.2011.06.011_bib0115","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.neuroscience.2004.09.043","article-title":"Expression of peroxisome proliferator-activated receptors (PPARs) and retinoic acid receptors (RXRs) in rat cortical neurons","volume":"130","author":"Cimini","year":"2005","journal-title":"Neuroscience"},{"key":"10.1016\/j.bbr.2011.06.011_bib0120","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.yexcr.2004.09.032","article-title":"Peroxisome proliferator-activated receptor gamma is expressed in hippocampal neurons and its activation prevents beta-amyloid neurodegeneration: role of Wnt signaling","volume":"304","author":"Inestrosa","year":"2005","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.bbr.2011.06.011_bib0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1399-5618.2008.00435.x","article-title":"Volumetric neuroimaging investigations in mood disorders: bipolar disorder versus major depressive disorder","volume":"10","author":"Konarski","year":"2008","journal-title":"Bipolar Disord"},{"key":"10.1016\/j.bbr.2011.06.011_bib0130","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.pscychresns.2006.11.002","article-title":"HPA axis dysfunction in unmedicated major depressive disorder and its normalization by pharmacotherapy correlates with alteration of neural activity in prefrontal cortex and limbic\/paralimbic regions","volume":"155","author":"Aihara","year":"2007","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.bbr.2011.06.011_bib0135","unstructured":"Evans CH, Stefanovic-Racic M, Lancaster J. Nitric oxide and its role in orthopaedic disease. Clin Orthop Relat Res 1995:275\u201394."},{"key":"10.1016\/j.bbr.2011.06.011_bib0140","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0031-6997(25)06663-3","article-title":"Nitric oxide: physiology, pathophysiology, and pharmacology","volume":"43","author":"Moncada","year":"1991","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.bbr.2011.06.011_bib0145","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0304-4165(03)00005-9","article-title":"Decreased activity and impaired induction of nitric oxide synthase by lipopolysaccharides in streptozotocin-induced diabetic rats","volume":"1620","author":"Khandelwal","year":"2003","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.bbr.2011.06.011_bib0150","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/sj.bjp.0704569","article-title":"NO as a signalling molecule in the nervous system","volume":"135","author":"Esplugues","year":"2002","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bbr.2011.06.011_bib0155","doi-asserted-by":"crossref","first-page":"11513","DOI":"10.1523\/JNEUROSCI.2259-06.2006","article-title":"Tonic and phasic nitric oxide signals in hippocampal long-term potentiation","volume":"26","author":"Hopper","year":"2006","journal-title":"J Neurosci"},{"key":"10.1016\/j.bbr.2011.06.011_bib0160","doi-asserted-by":"crossref","first-page":"9344","DOI":"10.1523\/JNEUROSCI.1902-09.2009","article-title":"More than a retrograde messenger: nitric oxide needs two cGMP pathways to induce hippocampal long-term potentiation","volume":"29","author":"Taqatqeh","year":"2009","journal-title":"J Neurosci"},{"key":"10.1016\/j.bbr.2011.06.011_bib0165","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1097\/00001756-200011270-00022","article-title":"Evidence for dual effects of nitric oxide in the forced swimming test and in the tail suspension test in mice","volume":"11","author":"da Silva","year":"2000","journal-title":"Neuroreport"},{"key":"10.1016\/j.bbr.2011.06.011_bib0170","doi-asserted-by":"crossref","unstructured":"Harvey BH, Duvenhage I, Viljoen F, Scheepers N, Malan SF, Wegener G, et al. Role of monoamine oxidase, nitric oxide synthase and regional brain monoamines in the antidepressant-like effects of methylene blue and selected structural analogues. Biochem Pharmacol 2010.","DOI":"10.1016\/j.bcp.2010.07.037"},{"key":"10.1016\/j.bbr.2011.06.011_bib0175","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.bbr.2008.12.032","article-title":"A role for nitrergic system in the antidepressant-like effects of chronic lithium treatment in the mouse forced swimming test","volume":"200","author":"Ghasemi","year":"2009","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.bbr.2011.06.011_bib0180","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.bcp.2010.07.037","article-title":"Role of monoamine oxidase, nitric oxide synthase and regional brain monoamines in the antidepressant-like effects of methylene blue and selected structural analogues","volume":"80","author":"Harvey","year":"2010","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bbr.2011.06.011_bib0185","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0165-6147(02)02017-5","article-title":"Assessing antidepressant activity in rodents: recent developments and future needs","volume":"23","author":"Cryan","year":"2002","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.bbr.2011.06.011_bib0190","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00213-009-1609-1","article-title":"NMDA receptor\/nitrergic system blockage augments antidepressant-like effects of paroxetine in the mouse forced swimming test","volume":"206","author":"Ghasemi","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.bbr.2011.06.011_bib0195","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1097\/00001756-200006260-00008","article-title":"Acute treatments with GMP produce antidepressant-like effects in mice","volume":"11","author":"Eckeli","year":"2000","journal-title":"Neuroreport"},{"key":"10.1016\/j.bbr.2011.06.011_bib0200","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00213-002-1335-4","article-title":"Antidepressant-like effects in various mice strains in the forced swimming test","volume":"166","author":"David","year":"2003","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.bbr.2011.06.011_bib0205","first-page":"327","article-title":"Behavioral despair in mice: a primary screening test for antidepressants","volume":"229","author":"Porsolt","year":"1977","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"10.1016\/j.bbr.2011.06.011_bib0210","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1006\/meth.1996.0074","article-title":"The use of aminoguanidine, a selective iNOS inhibitor, to evaluate the role of nitric oxide in the development of autoimmune diabetes","volume":"10","author":"Corbett","year":"1996","journal-title":"Methods"},{"key":"10.1016\/j.bbr.2011.06.011_bib0215","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0166-4328(03)00069-X","article-title":"Involvement of NMDA receptors and l-arginine-nitric oxide pathway in the antidepressant-like effects of zinc in mice","volume":"144","author":"Rosa","year":"2003","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.bbr.2011.06.011_bib0220","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.euroneuro.2003.08.010","article-title":"Nitric oxide synthase inhibitors augment the effects of serotonin re-uptake inhibitors in the forced swimming test","volume":"14","author":"Harkin","year":"2004","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.bbr.2011.06.011_bib0225","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00210-009-0467-z","article-title":"Opposite effects of milnacipran, a serotonin norepinephrine reuptake inhibitor, on the levels of nitric oxide and brain-derived neurotrophic factor in mouse brain cortex","volume":"380","author":"Ikenouchi-Sugita","year":"2009","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.bbr.2011.06.011_bib0230","doi-asserted-by":"crossref","first-page":"8225","DOI":"10.1523\/JNEUROSCI.1652-09.2009","article-title":"Suppression of spreading depression-like events in locusts by inhibition of the NO\/cGMP\/PKG pathway","volume":"29","author":"Armstrong","year":"2009","journal-title":"J Neurosci"},{"key":"10.1016\/j.bbr.2011.06.011_bib0235","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.brainresbull.2010.01.010","article-title":"Behavioral, biochemical and cellular correlates in the protective effect of sertraline against transient global ischemia induced behavioral despair: possible involvement of nitric oxide-cyclic guanosine monophosphate study pathway","volume":"82","author":"Gaur","year":"2010","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.bbr.2011.06.011_bib0240","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ejphar.2007.05.002","article-title":"Possible involvement of L-arginine-nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) signaling pathway in the antidepressant activity of berberine chloride","volume":"569","author":"Kulkarni","year":"2007","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bbr.2011.06.011_bib0245","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ejphar.2007.04.028","article-title":"Involvement of nitric oxide (NO) signaling pathway in the antidepressant action of bupropion, a dopamine reuptake inhibitor","volume":"568","author":"Dhir","year":"2007","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bbr.2011.06.011_bib0250","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.pnpbp.2007.02.008","article-title":"Involvement of l-arginine-nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effect of venlafaxine in mice","volume":"31","author":"Dhir","year":"2007","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.bbr.2011.06.011_bib0255","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s00125-006-0159-x","article-title":"Depression as a risk factor for the onset of type 2 diabetes mellitus. A meta-analysis","volume":"49","author":"Knol","year":"2006","journal-title":"Diabetologia"},{"key":"10.1016\/j.bbr.2011.06.011_bib0260","doi-asserted-by":"crossref","first-page":"934","DOI":"10.2337\/diacare.23.7.934","article-title":"Depression and poor glycemic control: a meta-analytic review of the literature","volume":"23","author":"Lustman","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bbr.2011.06.011_bib0265","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/00006842-200107000-00015","article-title":"Association of depression and diabetes complications: a meta-analysis","volume":"63","author":"de Groot","year":"2001","journal-title":"Psychosom Med"},{"key":"10.1016\/j.bbr.2011.06.011_bib0270","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1023\/A:1008817812520","article-title":"The role of anxiety and depression in quality of life and symptom reporting in people with diabetes mellitus","volume":"7","author":"Kohen","year":"1998","journal-title":"Qual Life Res"},{"key":"10.1016\/j.bbr.2011.06.011_bib0275","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1111\/j.1572-0241.2001.03605.x","article-title":"Psychological distress is linked to gastrointestinal symptoms in diabetes mellitus","volume":"96","author":"Talley","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.bbr.2011.06.011_bib0280","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2337\/diacare.29.02.06.dc05-1572","article-title":"Cost-effectiveness and net benefit of enhanced treatment of depression for older adults with diabetes and depression","volume":"29","author":"Katon","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bbr.2011.06.011_bib0285","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejphar.2005.11.049","article-title":"Modulation of the oxidative stress and inflammatory response by PPAR-gamma agonists in the hippocampus of rats exposed to cerebral ischemia\/reperfusion","volume":"530","author":"Collino","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bbr.2011.06.011_bib0290","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1100\/tsw.2010.32","article-title":"Rosiglitazone add-on in treatment of depressed patients with insulin resistance: a pilot study","volume":"10","author":"Rasgon","year":"2010","journal-title":"Sci World J"},{"key":"10.1016\/j.bbr.2011.06.011_bib0295","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1517\/14656566.8.11.1615","article-title":"Thiazolidinediones: novel treatments for cognitive deficits in mood disorders?","volume":"8","author":"McIntyre","year":"2007","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.bbr.2011.06.011_bib0300","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1517\/14656566.7.10.1305","article-title":"Managing psychiatric disorders with antidiabetic agents: translational research and treatment opportunities","volume":"7","author":"McIntyre","year":"2006","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.bbr.2011.06.011_bib0305","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1210\/er.20.5.649","article-title":"Peroxisome proliferator-activated receptors: nuclear control of metabolism","volume":"20","author":"Desvergne","year":"1999","journal-title":"Endocr Rev"},{"key":"10.1016\/j.bbr.2011.06.011_bib0310","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1176\/jnp.3.4.387","article-title":"Hippocampal abnormalities in depression","volume":"3","author":"Krishnan","year":"1991","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"10.1016\/j.bbr.2011.06.011_bib0315","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.expneurol.2008.03.008","article-title":"Neuroprotective effect of the new thiadiazolidinone NP00111 against oxygen-glucose deprivation in rat hippocampal slices: implication of ERK1\/2 and PPARgamma receptors","volume":"212","author":"Rosa","year":"2008","journal-title":"Exp Neurol"},{"key":"10.1016\/j.bbr.2011.06.011_bib0320","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1111\/j.1471-4159.2009.06107.x","article-title":"Distinct modulation of voltage-gated and ligand-gated Ca2+ currents by PPAR-gamma agonists in cultured hippocampal neurons","volume":"109","author":"Pancani","year":"2009","journal-title":"J Neurochem"},{"key":"10.1016\/j.bbr.2011.06.011_bib0325","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.expneurol.2009.01.002","article-title":"Autoradiographical imaging of PPARgamma agonist effects on PBR\/TSPO binding in TASTPM mice","volume":"216","author":"Roberts","year":"2009","journal-title":"Exp Neurol"},{"key":"10.1016\/j.bbr.2011.06.011_bib0330","doi-asserted-by":"crossref","first-page":"6862","DOI":"10.1523\/JNEUROSCI.20-18-06862.2000","article-title":"Peroxisome proliferator-activated receptor-gamma ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo","volume":"20","author":"Heneka","year":"2000","journal-title":"J Neurosci"},{"key":"10.1016\/j.bbr.2011.06.011_bib0335","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0304-3940(99)00055-5","article-title":"Activators of peroxisome proliferator-activated receptor-gamma (PPARgamma) inhibit inducible nitric oxide synthase expression but increase heme oxygenase-1 expression in rat glial cells","volume":"262","author":"Kitamura","year":"1999","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.bbr.2011.06.011_bib0340","doi-asserted-by":"crossref","unstructured":"Allami N, Javadi-Paydar M, Rayatnia F, Sehhat K, Rahimian R, Norouzi A, et al. Suppression of nitric oxide synthesis by l-NAME reverses the beneficial effects of pioglitazone on scopolamine-induced memory impairment in mice. Eur J Pharmacol 2010.","DOI":"10.1016\/j.ejphar.2010.10.007"},{"key":"10.1016\/j.bbr.2011.06.011_bib0345","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.neuroscience.2004.10.021","article-title":"Peroxisome proliferator-activated receptor-gamma ligands reduce inflammation and infarction size in transient focal ischemia","volume":"130","author":"Sundararajan","year":"2005","journal-title":"Neuroscience"},{"key":"10.1016\/j.bbr.2011.06.011_bib0350","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1093\/brain\/awh452","article-title":"Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice","volume":"128","author":"Heneka","year":"2005","journal-title":"Brain"},{"key":"10.1016\/j.bbr.2011.06.011_bib0355","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/sj.jcbfm.9600182","article-title":"Rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2 cause potent neuroprotection after experimental stroke through noncompletely overlapping mechanisms","volume":"26","author":"Pereira","year":"2006","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.bbr.2011.06.011_bib0360","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/j.1460-9568.2009.06657.x","article-title":"PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease","volume":"29","author":"Schintu","year":"2009","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.bbr.2011.06.011_bib0365","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1046\/j.1471-4159.2002.00990.x","article-title":"Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease","volume":"82","author":"Breidert","year":"2002","journal-title":"J Neurochem"},{"key":"10.1016\/j.bbr.2011.06.011_bib0370","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/ana.10206","article-title":"Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis","volume":"51","author":"Feinstein","year":"2002","journal-title":"Ann Neurol"},{"key":"10.1016\/j.bbr.2011.06.011_bib0375","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/jnr.10501","article-title":"Effects of peroxisome proliferator-activated receptor-gamma agonists on central nervous system inflammation","volume":"71","author":"Kielian","year":"2003","journal-title":"J Neurosci Res"},{"key":"10.1016\/j.bbr.2011.06.011_bib0380","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.1460-9568.2005.04200.x","article-title":"The intracerebral application of the PPARgamma-ligand pioglitazone confers neuroprotection against focal ischaemia in the rat brain","volume":"22","author":"Zhao","year":"2005","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.bbr.2011.06.011_bib0385","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2174\/092986709787458399","article-title":"Modulation of microglial innate immunity in Alzheimer's disease by activation of peroxisome proliferator-activated receptor gamma","volume":"16","author":"Shie","year":"2009","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.bbr.2011.06.011_bib0390","doi-asserted-by":"crossref","first-page":"H742","DOI":"10.1152\/ajpheart.00718.2003","article-title":"PPARgamma activation, by reducing oxidative stress, increases NO bioavailability in coronary arterioles of mice with Type 2 diabetes","volume":"286","author":"Bagi","year":"2004","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.bbr.2011.06.011_bib0395","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1161\/01.ATV.0000044461.01844.C9","article-title":"Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells","volume":"23","author":"Calnek","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.bbr.2011.06.011_bib0400","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.brainres.2010.11.062","article-title":"Neuroprotective effects of KR-62980, a new PPARgamma agonist, against chemical ischemia-reperfusion in SK-N-SH cells","volume":"1372","author":"Kim","year":"2011","journal-title":"Brain Res"},{"key":"10.1016\/j.bbr.2011.06.011_bib0405","doi-asserted-by":"crossref","first-page":"5004","DOI":"10.4049\/jimmunol.180.7.5004","article-title":"The synthetic peroxisome proliferator-activated receptor-gamma agonist ciglitazone attenuates neuroinflammation and accelerates encapsulation in bacterial brain abscesses","volume":"180","author":"Kielian","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.bbr.2011.06.011_bib0410","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.neurobiolaging.2007.09.001","article-title":"Interleukin-4 mediates the neuroprotective effects of rosiglitazone in the aged brain","volume":"30","author":"Loane","year":"2009","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.bbr.2011.06.011_bib0415","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/nen.0b013e318040cfa2","article-title":"Nitric oxide synthase 3-mediated neurodegeneration after intracerebral gene delivery","volume":"66","author":"de la Monte","year":"2007","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.bbr.2011.06.011_bib0420","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1017\/S146114570800967X","article-title":"Noradrenaline reuptake inhibitors limit neuroinflammation in rat cortex following a systemic inflammatory challenge: implications for depression and neurodegeneration","volume":"12","author":"O'Sullivan","year":"2009","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.bbr.2011.06.011_bib0425","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.brainres.2010.06.034","article-title":"Anticonvulsant potential of the peroxisome proliferator-activated receptor gamma agonist pioglitazone in pentylenetetrazole-induced acute seizures and kindling in mice","volume":"1351","author":"Abdallah","year":"2010","journal-title":"Brain Res."}],"container-title":["Behavioural Brain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432811004712?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432811004712?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T18:25:47Z","timestamp":1741285547000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166432811004712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":85,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S0166432811004712"],"URL":"https:\/\/doi.org\/10.1016\/j.bbr.2011.06.011","relation":{},"ISSN":["0166-4328"],"issn-type":[{"value":"0166-4328","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}